Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2161882
Abstract: ABSTRACT Introduction Cognitive impairment (CI) is a core feature of Multiple Sclerosis (MS), being detectable in up to 65% of subjects. Treatment of CI can be considered of paramount importance. However, no standardized strategies are… read more here.
Keywords: advances pharmacological; pharmacological prevention; management; current advances ... See more keywords
Perception of pharmacological prevention and subsequent non-adherence to medication in patients with ischaemic heart disease: a population-based cohort study
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-054362
Abstract: Objective A patient-focused approach is advocated to embody risk of non-adherence to medication and subsequent adverse clinical outcomes following ischaemic heart disease (IHD). This study aimed to explore how patient perceived information on pharmacological prevention… read more here.
Keywords: medication; non; non persistence; pharmacological prevention ... See more keywords